CSF3 and infection: Patients—who received prophylactic G-CSF at least once and who did not—respectively developed the following TEAEs: grade 3–5 blood and lymphatic system disorders (MedDRA), 3 cases (18.8%) and 7 cases (31.8%); and grade 3–5 infections and infestations (MedDRA), 1 case (6.3%) and 6 cases (27.3%).